Eloralintide
Selective amylin agonist; 48-week phase 2 weight data.
Overview
Eloralintide (LY3841136) is an investigational long-acting amylin receptor agonist developed by Eli Lilly for chronic weight management, given once weekly by subcutaneous injection. What distinguishes it from most compounds in the obesity pipeline is selectivity: it is engineered to act at the amylin receptor without activating the GLP-1, GIP or glucagon receptors that drive semaglutide, tirzepatide and retatrutide. It is not approved by the FDA for any use and remains investigational; it is sold here for research purposes only, not as a prescription medicine. Some vendors list it under the brand name "Elora."
How it works
Amylin is a hormone co-secreted with insulin from pancreatic beta cells that signals satiety, slows gastric emptying and blunts post-meal glucagon release. Eloralintide is a peptide engineered for stability and for selective agonism at the amylin receptor (AMY1R), reducing appetite and food intake through a pathway that runs parallel to — rather than overlapping with — incretin receptor agonism.
That selectivity is the design intent rather than an incidental property. Cagrilintide, the other long-acting amylin agonist in late-stage development, also activates the calcitonin receptor; eloralintide is reported to avoid that cross-activation. Because the gastrointestinal burden of incretin drugs is tied to GLP-1 receptor agonism, a selective amylin agonist offers a plausible route to appetite suppression with a different tolerability profile — which is also the rationale for the registered trials pairing it with tirzepatide.
Evidence
Phase 1 established proof of concept: across dose groups, weight reduction reached roughly 2.6% to 11.3% by week 12, and gastrointestinal adverse events were comparatively infrequent (nausea 8%, vomiting 4%, diarrhoea 10%), with decreased appetite (19%), headache (12%) and fatigue (11%) more common.
The substantive result is the 48-week phase 2 trial (NCT06230523) in 263 adults with obesity, or overweight with at least one obesity-related comorbidity, and without type 2 diabetes. All eloralintide arms met the primary endpoint of superiority to placebo in percent body-weight change:
| Arm | Mean weight change at 48 weeks |
|---|---|
| 1 mg | −9.5% |
| 3 mg | −12.4% |
| 6 mg | −17.6% |
| 9 mg | −20.1% |
| 6/9 mg escalation | −19.9% |
| 3/6/9 mg escalation | −16.4% |
| Placebo | −0.4% |
Results were presented at ObesityWeek 2025 and published simultaneously in The Lancet.
Two caveats belong alongside those numbers. This is a phase 2 trial of 263 participants, not a phase 3 outcomes study, and the comparator was placebo rather than an active incretin agonist — so the figures do not establish how eloralintide performs head-to-head against tirzepatide or semaglutide. Phase 3 and combination trials are registered but had not reported at the time of writing.
Safety
In the phase 2 trial the most common adverse events were mild-to-moderate gastrointestinal symptoms and fatigue, occurring more frequently at higher doses; slower dose escalation was associated with lower incidence, and the 1 mg and 3 mg arms showed frequencies similar to placebo. Phase 1 reported decreased appetite, headache and fatigue as the leading events, with nausea and vomiting relatively uncommon for a compound in this therapeutic area.
Because eloralintide remains investigational, there are no long-term human safety data, no approved indication, and no established contraindications or interaction profile. Every figure above comes from company-sponsored trials of limited duration. Research use only — nothing here is therapeutic guidance or a dosing recommendation.
Reported side effects
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Decreased appetite
- Fatigue
- Headache
- Nausea (less frequent than with incretin agonists)
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
Cautions discuss with a clinician
- No established human contraindications exist because eloralintide is investigational; formal labeled contraindications have not been defined.
- Pregnancy and breastfeeding — no human safety data; weight-loss agents are generally avoided in pregnancy.
- Known hypersensitivity to eloralintide or excipients; long-term human safety is uncharacterized.
- Incretin agonists (e.g. tirzepatide, semaglutide)Deliberately studied in combination in registered trials; additive appetite and gastrointestinal effects are plausible, but no formal interaction profile is established (research use only).
Timeline commonly reported
- Weeks 1–12
Phase 1 saw weight reduction of roughly 2.6%–11.3% across dose groups by week 12, with gastrointestinal events infrequent relative to incretin agonists.
- Weeks 12–48
In the 48-week phase 2 trial, weight loss continued to accrue across all dose arms rather than plateauing early.
- Week 48
Phase 2 primary endpoint: mean weight reduction of 9.5% (1 mg) to 20.1% (9 mg) versus 0.4% for placebo.
FAQ
Is eloralintide FDA-approved?
No. Eloralintide is an investigational compound from Eli Lilly. It has completed phase 1 and a 48-week phase 2 trial and has not been approved for any use by the FDA or any other regulator. It is sold here research-use-only.
How is it different from cagrilintide?
Both are long-acting amylin receptor agonists, but eloralintide is engineered to be selective for the amylin receptor, whereas cagrilintide also acts at the calcitonin receptor. Eloralintide likewise avoids the GLP-1, GIP and glucagon receptors that drive tirzepatide and retatrutide.
What weight-loss figures were reported?
In a 48-week phase 2 trial in 263 adults with obesity or overweight, mean weight reduction ranged from 9.5% in the 1 mg arm to 20.1% in the 9 mg arm, against 0.4% for placebo. Every dose arm met the primary endpoint. Results were presented at ObesityWeek 2025 and published in The Lancet.
Why is its tolerability described as favourable?
Amylin receptor agonism drives satiety through a different pathway than GLP-1 receptor agonism, and in trials the nausea and vomiting characteristic of incretin drugs were comparatively infrequent — phase 1 reported nausea in 8% and vomiting in 4%. In phase 2 the most common events were mild-to-moderate gastrointestinal symptoms and fatigue, more frequent at higher doses, with the 1 mg and 3 mg arms close to placebo.
How was it dosed in trials?
By once-weekly subcutaneous injection. The phase 2 trial studied fixed 1, 3, 6 and 9 mg arms alongside stepwise escalation arms (6/9 mg and 3/6/9 mg). Slower escalation was associated with fewer adverse events. These are investigational regimens, not dosing guidance.
Is it being studied with other compounds?
Yes. Registered trials include eloralintide combined with tirzepatide, and combinations in people with type 2 diabetes. Those readouts are separate from the monotherapy phase 2 results above.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.